FORT LAUDERDALE, Fla., Oct. 7 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, announced today that its distributor The Oyamo group has place an order for the first CT Laser Mammography System (CTLM(R)) for Jerusalem, Israel.
The Oyamo group obtained the import license from the Israel Ministry of Health which permitted the shipment and initiated the purchase order. The CTLM system will be placed in the prestigious hospital Hadassah, located in the heart of Jerusalem. The Hadassah University Medical Center is a tertiary care referral facility, known for pioneering new medical techniques. A premier teaching hospital and research center, the Medical Center is equipped with the most sophisticated diagnostic, treatment and research equipment enabling its world renowned faculty to furnish the most modern medical care in an atmosphere that embraces excellence.
Dr. Miri Sklair, Head of Hadassah's Department of Mammography, will use the CTLM(R) system in addition to Mammography and Ultrasound in detecting breast cancer. Mr. Offer Hameiri, President of the Oyamo Group, quoted that he is "excited that a prestigious Medical Institution such as Hadassah, is going to be the pioneer for CTLM(R) in Israel."
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary breast imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CTLM is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: http://www.imds.com.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
|SOURCE Imaging Diagnostic Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved